Results from the TRIUMPH-4 trial, published in December 2025, showed participants with obesity and knee osteoarthritis taking retatrutide 12mg lost an average of 28.7% of their body weight at 68 weeks
No studies have directly compared the effects of retatrutide and other GLP-1 medications, but vomiting may have been slightly more common in retatrutide trials than in trials for currently available options
Development of GLP-1 Drugs Decades after the discovery of the natural hormone, there are now several available GLP-1 drugsor GLP-1 receptor agoniststhat can be used to treat diabetes, obesity, and other conditions
Discontinuation rates: Semaglutide has a meaningfully better tolerability profile
[PMC free article: PMC12595549] [PubMed: 41203232] 199
Skin preparation : Clean the injection site with an alcohol swab and allow it to dry completely before injection